Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer

Launched by UMEÅ UNIVERSITY · Nov 2, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how different schedules for radiation therapy can help men with newly diagnosed prostate cancer that has spread to other parts of the body, but only in a limited way. The researchers want to see if giving radiation in different ways can improve treatment outcomes for these patients. To be eligible for the study, participants need to have confirmed prostate cancer and a specific low amount of spread (like a maximum of four spots in the bones or any number of affected lymph nodes). They also need to be able to follow the study's procedures and give their consent to participate.

If you or a loved one decides to join this trial, you will receive radiation treatment for your prostate cancer. The study is currently recruiting men aged 65 to 74, and participants will be carefully monitored throughout the trial. It's important to note that those with more extensive metastatic disease or certain health issues may not be eligible. Overall, this trial aims to find the best way to deliver radiation to help improve the quality of life and outcomes for men with metastatic hormone-sensitive prostate cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Signed Informed Consent
• • 2. Histological confirmed prostate cancer
• • 3. Indication for early palliative radiation therapy of low burden metastatic prostate cancer. Low burden as defined by modified CHAARTED trial criteria to maximum 4 skeletal mets at any site and/or any number of lymph nodes
• • 4. baseline E-PROM
• Exclusion Criteria:
• • 1. High burden metastatic prostate cancer including all with visceral mets.
• • 2. Unable to comply with study procedures.
• • 3. Other diseases or medication that will put the patient at risk for more toxicity from radiotherapy
• • 4. Radiation treatment start later than nine months after the prostate cancer diagnosis.
• • 5. Severe micturition problems, IPSS \> 20 ( International Prostate Symptom Score)